Astral Systems raises £23M for medical isotopes

Astral Systems has secured a £23 million first close led by Mercia Ventures, bringing total funding past £28 million. The Bristol startup will scale production of medical radioisotopes for cancer diagnosis and treatment, targeting market availability by early 2027. Its multi-state fusion reactors are already operational at Technology Readiness Level 9.